{
  "docId": "019de076-08a6-76d8-a7d9-b68643d71f6f",
  "docSlug": "3a0354fd1e64f16191ffa0e33db132fd",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 19 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 19,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide highlights the transition from RUO to cGMP capabilities across the product line.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/9",
  "deckHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f",
  "deckJsonHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json",
  "deckAnchorHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.4,
        "y": 0.15
      },
      "kind": "image",
      "text": "ExPERT Instrument Portfolio (ATx, STx, GTx, VLx)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fae2145f-e7d8-40a0-a3c2-c022ca267d6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.4,
        "y": 0.55
      },
      "kind": "list",
      "text": "High Performance: >90% transfection efficiencies, >90% cell viabilities, Computer-controlled system. Flexibility: Single, fully-defined, animal component-free buffer, Pre-loaded library. Scalability: 75,000 to 7 million cells in seconds, Up to 20 billion cells in <30 mins, Up to 200 billion cells in <30 mins. High Quality: Sterile, single-use PAs, Closed, cGMP-compliant, ISO-certified, CE marked, FDA Master File.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3e16af1-b094-4cfb-befb-b789bbfecb8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.35,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Launched in 2019 based on MaxCyte’s proprietary Flow Electroporation® technology... Leverages the reversible permeability... Universally delivers molecules... Agnostic to cell type... Enables customers to use a single platform... Supported by a robust intellectual property portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eea50005-045f-43db-9e3b-9874d09d357e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6926f7a2-7ab2-4fd9-8d71-e3b994b7f96f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "778bc7f7-82ab-4f9e-b13f-7f4493657027",
      "evidence": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering, targeted at customers in the cell therapy and drug discovery markets.",
      "confidence": 0.7
    },
    {
      "name": "Value Proposition Canvas",
      "slug": "value-proposition-canvas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "dbb3d6b9-666f-4844-8a79-f0ec2fc91d06",
      "evidence": "Enabling customers to use... Agnostic to cell type... High Performance: >90% transfection efficiencies, >90% cell viabilities",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "c85bce06-a0b6-4a3f-abe1-f93499e324ad",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 8-9 present the ExPERT platform as a solution to industry challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "01f711fa-869f-4bfb-90f0-c7ddf9b8181f",
      "evidence": "The deck implies that not investing in cell-based therapies would mean missing out on significant market opportunity.",
      "position": 0,
      "objective": "What if we don't invest in cell-based therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}